Skip to main content
Menu

Endocrinology - Monthly Reports

List of monthly reports on Endocrinology

Endocrinology Research Analysis

June 2026 endocrinology research was driven by breakthroughs in incretin pharmacology, RNA biology, and precision therapeutics. Oral small‑molecule GLP‑1 receptor agonists advanced in both diabetes (elecoglipron) and obesity (HRS‑7535), indicating a coming shift beyond injectables. Mechanistic and translational studies refined precision use of incretins (metabolic‑state–dependent islet vs brain actions) and highlighted genotype‑specific risks from common agents (melatonin in MTNR1B carriers). Li

Endocrinology Research Analysis

May 2026 endocrinology research converged on durable metabolic therapy, organelle-targeted mechanisms, and precision diagnostics. Late-phase trials showed that continuing incretin therapy and switching to oral GLP-1 can maintain weight loss, while semaglutide provided pharmacologic rescue after suboptimal bariatric outcomes. Mechanistic studies advanced organelle biology (mitochondrial fission and peroxisome–lysosome ether lipids) and identified glucosamine–mTORC1 signaling as a mediator of gluc

Endocrinology Research Analysis

April 2026 endocrinology delivered mechanistic-to-clinic advances spanning obesity, diabetes, and environmental endocrine risk. A Cell study uncovered a skin–hypothalamus KLK14–LRRC7 pathway that imprints prior heat exposure into durable metabolic vulnerability, reframing climate exposure as an endocrine risk factor. Two randomized human signals shaped obesity care: cagrilintide plus semaglutide outperformed semaglutide alone in a phase 3a East Asian trial, while a prespecified SELECT analysis r

Endocrinology Research Analysis

In March 2026, endocrinology advanced along two converging axes: mechanistic rewiring of metabolic flux and tangible prevention/therapeutic gains. Breakthroughs mapped an intestinal–lymphatic gateway for dietary fat (GPR182) and a mitochondrial PEP shuttle (SLC25A35) that controls hepatic glycerolipid synthesis, while neuroimmune control of GnRH reframed reproductive endocrinology. Clinically, primary prevention with PCSK9 inhibition in high‑risk diabetes and double‑digit weight loss with a dual

Endocrinology Research Analysis

February’s endocrinology research spotlighted immunometabolic control of glucose with a thromboxane axis that enhances muscle glucose uptake, alongside translational advances that can immediately shape care. Pelacarsen achieved profound Lp(a) lowering and sharply reduced apheresis utilization in secondary prevention, while once‑weekly somapacitan proved non‑inferior to daily growth hormone in idiopathic short stature, reducing treatment burden. Foundational biology progressed with a human NKX2.2

Endocrinology Research Analysis

January’s endocrinology literature converged on tractable mechanisms spanning vascular–endocrine crosstalk, mitochondrial fuel control, adipose–bone signaling, sex-specific hepatocyte GPCRs, and embryo transcriptional regulation. Top studies defined an endothelial IRE1α–THBS1 checkpoint that supports islet vascular adaptation, a mitochondrial carrier (SLC25A45) essential for carnitine biosynthesis and fuel switching, and an adipocyte-selective sclerostin loop3–LRP4 axis that perturbs systemic me

Endocrinology Research Analysis

Endocrinology in December 2025 featured practice-changing evidence in reproductive medicine and mechanistic advances in β-cell biology and metabolic programming. Two large IVF studies collectively undermined routine use of PGT-A labels (particularly mosaicism) and showed no live-birth benefit of PGT-A in severe male factor ICSI, supporting de-implementation. Translational metabolism highlighted ENPP2/LPA signaling as a druggable β-cell compensation axis and an EV–AMPK–αKG pathway linking exclusi

Endocrinology Research Analysis

November endocrinology was defined by outcome-changing lipid therapeutics and mechanistic advances. Two NEJM trials showed that APOC3 antisense therapy (olezarsen) not only lowers triglycerides but also reduces acute pancreatitis in severe hypertriglyceridemia. Another NEJM trial extended the benefit of PCSK9 inhibition (evolocumab) into primary prevention. Mechanistic work in Science revealed the adipogenin–seipin axis as a structural regulator of lipid droplet biogenesis, highlighting new targ

Endocrinology Research Analysis

October’s endocrinology research converged on β-cell restoration, immunometabolic control, and digitally enabled care. Human islet transcriptomics defined recovery signatures that prioritize disease-modifying targets for type 2 diabetes, while mechanistic work mapped a TRAF6-governed mitophagy node and the SGLT2→SAM/H3K27me3 epigenetic axis. Clinically, a Bayesian decision support system safely lowered HbA1c in adults with type 1 diabetes on multiple daily injections, and prevention data reaffir

Endocrinology Research Analysis

September’s endocrinology literature (limited weekly coverage) converged on kidney-centric endocrine–cardiometabolic axes. A microbiota-derived peptide (corisin) linked to cellular senescence emerged as a druggable mediator of diabetic kidney fibrosis with monoclonal antibody proof-of-concept in mice. A mechanistic study connected branched-chain amino acid dysmetabolism to podocyte PKM2-driven apoptosis, nominating metabolic restoration strategies for DKD. Clinically, a phase 3 RCT of the aldost

Endocrinology Research Analysis

August’s endocrinology research converged on mechanistic targets and translational tools across metabolic and reproductive axes. Functional genomics linked DENND1A regulatory activity to androgen excess in PCOS, while autophagy–SNARE dysfunction (G3BP1) and immunometabolic targeting (ACLY) refined therapeutic strategies for MASLD/MASH and MASH‑HCC. A large randomized trial indicated SADI‑S yields superior two‑year weight loss vs RYGB, and fluorescent dual GLP1R/GIPR agonist probes enabled direct

Endocrinology Research Analysis

July’s endocrinology literature converged on translational mechanisms and near-term therapies. A metabolite–inflammatory hub (PGK1) emerged as a druggable driver of diabetic kidney disease with repurposable antagonists, while mitochondrial proteostasis via LONP1–mtHSP70 was identified as a central node in β-cell failure. Islet microcircuit biology advanced with GLP1R pre-internalization guiding alpha-to-beta signaling, and deep phenotyping with a multi-modal AI model improved metabolic risk pred

Endocrinology Research Analysis

June’s endocrinology literature was led by long-acting anti-obesity and diabetes therapeutics, including a monthly GLP-1/GIP-pathway agent with double-digit weight loss and large phase 3 trials validating once-weekly basal insulin and dual-incretin combinations. Mechanistic and preclinical advances introduced a creatine-dependent thermogenic drug (SANA) and an epigenetic β-cell identity axis (BRD4–ATF5) as emerging targets. Complementary work across the month reinforced biomarker-guided stratifi

Endocrinology Research Analysis

In May 2025, endocrinology research emphasized translational advances spanning metabolic liver disease and diabetic complications. A pivotal phase 3 RCT showed that once-weekly semaglutide 2.4 mg achieved histologic benefits in MASH with F2–F3 fibrosis. Complementary mechanistic work mapped a mycobiome-driven CerS6–ceramide axis as a druggable pathway in steatohepatitis. In diagnostics, a multi-ethnic, prospectively tested deep-learning system using retinal images enabled scalable detection and

Endocrinology Research Analysis

April’s endocrinology research converged on spatial and cellular reprogramming in adipose and liver metabolism, alongside a sharpened neuroendocrine link between peripheral metabolic state and behavior. A Science study uncovered age-enriched adipose progenitors (CP‑A) dependent on LIFR signaling that drive visceral adipogenesis, while two liver studies revealed plastic zonation of gluconeogenesis and a hepatoprotective ketogenesis axis extending beyond fat oxidation. A Nature Metabolism report d

Endocrinology Research Analysis

March 2025 endocrinology research linked fundamental mechanisms to practice-changing interventions. A first-in-class small molecule that directly modulates BMAL1 opened a new path for circadian pharmacology, while a mechanistic RCT showed sucralose acutely heightens hypothalamic appetite signaling. Outcome-level clinical evidence consolidated automated insulin delivery for insulin-treated type 2 diabetes and established oral semaglutide as an oral GLP-1 with cardiovascular benefit. In liver–meta

Endocrinology Research Analysis

February endocrinology research converged on neuroendocrine circuit mapping, adipose data infrastructure, and modifiable epigenetic mechanisms. A human hypothalamus spatio-cellular atlas and a Science study on a thalamic mu-opioid circuit for sugar appetite highlight actionable neural targets for obesity. A large adipose multi-omics portal (adiposetissue.org) standardizes >6,000 human datasets, accelerating biomarker and target discovery, while a Nature Communications–aligned theme emphasized ly

Endocrinology Research Analysis

Endocrinology in January 2025 was defined by inter-organ endocrine circuits and pragmatic, implementation-ready trials. Science reports uncovered a muscle–pituitary myostatin axis driving FSH and a fasting-activated intestinal neuron→ILC2→pancreas circuit regulating glucagon, reframing systemic endocrine control. Translational advances included a multicenter RCT showing dapagliflozin added to structured calorie restriction substantially increases type 2 diabetes remission, and a Nature Communica